Traditional Chinese medicine formula for preventing and treating coronary heart disease and preparation method thereof

Abstract

The traditional Chinese medicine formula comprises the following components in parts by mass: 100 parts of sea-buckthorn, 100 parts of rhinacanthus nasutus, 100 parts of dioscorea panthaica, 100 parts of ixeris sonchifolia hance, 100 parts of salvia miltiorrhiza, 100 parts of rhodobryum roseum, 60 parts of pseudo-ginseng, 60 parts of ligusticum chuanxiong hort, 60 parts of bistort rhizome, 60 parts of radix ophiopogonis, 60 parts of pimpinella thellungiana, 50 parts of leonurus, 50 parts of radix puerariae and 50 parts of herba epimedii. According to the theory of dialectical treatment of traditional Chinese medicine, the traditional Chinese medicine has the effects of tonifying deficiency, purging excess, treating both symptoms and root causes, regulating qi and blood and treating coronary heart disease complications, and has a good curative effect of preventing and treating coronary heart disease.

Description

Technical Field

[0001] This invention relates to the field of biomedicine, specifically to a traditional Chinese medicine formula for the prevention and treatment of coronary heart disease and its preparation method. Background Technology

[0002] Coronary heart disease (CAD) is a heart condition caused by narrowing or blockage of the coronary arteries, leading to myocardial ischemia, hypoxia, and even necrosis. It is also known as ischemic heart disease. This type of disease falls under the category of blood stasis syndrome in Traditional Chinese Medicine (TCM). In clinical practice, TCM formulas that promote blood circulation and remove blood stasis are used to treat angina pectoris and cerebral arteriosclerosis in CAD, which can alleviate symptoms and improve the blood supply to the coronary arteries.

[0003] Patent 201410662598.0 discloses a traditional Chinese medicine formula for treating coronary heart disease in the elderly, including Cistanche deserticola, Rehmannia glutinosa, Lycium barbarum, Astragalus membranaceus, Codonopsis pilosula, Ophiopogon japonicus, Schisandra chinensis, Salvia miltiorrhiza, Angelica sinensis, Ligusticum chuanxiong, Trichosanthes kirilowii, Poria cocos, Atractylodes macrocephala, Glycyrrhiza uralensis, and Panax notoginseng. Although this formula mainly focuses on tonifying both Qi and Yin and promoting blood circulation, it is insufficient in warming Yang and unblocking the meridians, has a weak ability to resolve phlegm and turbidity, cannot regulate blood lipids, and has a weak ability to resist arteriosclerosis.

[0004] Patent 201310184617.9 discloses a traditional Chinese medicine for treating coronary heart disease caused by phlegm and turbidity obstruction, including Ophiopogon japonicus, Schisandra chinensis, Cinnamomum cassia, Rehmannia glutinosa, Salvia miltiorrhiza, Ligusticum chuanxiong, and Leonurus japonicus. This traditional Chinese medicine formula has weak phlegm-resolving and turbidity-removing effects, insufficient warming and blood-activating properties, does not cover common complications of coronary heart disease, lacks lipid-lowering components, and does not contain cardiotonic drugs. From the perspective of traditional Chinese medicine theory, the therapeutic effect on coronary heart disease is relatively weak. At the same time, the components and quantities in the formula are consistent, and the composition of the components is not matched according to the theory of monarch, minister, assistant, and guide in traditional Chinese medicine. The main and secondary components are not distinguished, and the therapeutic effect cannot be fully exerted. The therapeutic effect needs further experimental verification.

[0005] The key challenge in leveraging the advantages of traditional Chinese medicine lies in optimizing the composition of Chinese herbal medicines to match the principles of compatibility, addressing both the symptoms and the root cause, and simultaneously treating complications of coronary heart disease. Summary of the Invention

[0006] The purpose of this invention is to overcome the shortcomings of the prior art and provide a traditional Chinese medicine formula for the prevention and treatment of coronary heart disease and its preparation method. According to the theory of traditional Chinese medicine compatibility, it has been experimentally verified to have a good therapeutic effect on coronary heart disease.

[0007] The objective of this invention is achieved through the following technical solution: a traditional Chinese medicine formula for the prevention and treatment of coronary heart disease, comprising, by weight, 100 parts of sea buckthorn, 100 parts of white crane lingzhi grass, 100 parts of yellow yam, 100 parts of bitter gourd, 100 parts of salvia miltiorrhiza, 100 parts of purslane, 60 parts of notoginseng, 60 parts of chuanxiong, 60 parts of bistorta, 60 parts of ophiopogon japonicus, 60 parts of yanghong tan, 50 parts of motherwort, 50 parts of kudzu root, and 50 parts of epimedium.

[0008] A method for preparing a traditional Chinese medicine formula for the prevention and treatment of coronary heart disease includes the following steps: S1. Weigh out the Chinese medicinal materials according to the specified proportions, mix them together, and process them into 600-1000 mesh ultrafine powder; S2. Take half of the total amount of the above ultrafine powder, add 1000ml of purified water and 500ml of 75-degree liquor, and mix well in a stirrer. S3. Heat to 100℃ and hold for 30 minutes, then let it cool naturally to room temperature for 1 hour; S4. Mix the remaining half of the ultrafine powder with the ultrafine powder mixture after high-temperature treatment, dry it, and then make it into pellets or granules.

[0009] The present invention has the following advantages: 1. Coronary heart disease falls under the categories of "chest pain" and "palpitation" in traditional Chinese medicine. It is caused by deficiency of heart qi, insufficiency of heart yin, and decline of kidney yang (weak driving force), as well as blood stasis, phlegm obstruction, and qi stagnation and cold coagulation (obstruction of heart vessels). The Chinese medicine formula of this invention takes the principle of tonifying deficiency and purging excess as the treatment principle, treating both the root cause and the symptoms, and regulating qi and blood. 2. Sea buckthorn, sour, astringent, and warm, invigorates blood circulation, lowers lipids, resolves phlegm, and unblocks the meridians; Ganoderma lucidum, sweet and neutral, tonifies qi, calms the mind, and softens blood vessels; Salvia miltiorrhiza, bitter and slightly cold, removes blood stasis, relieves pain, clears the heart, and eliminates irritability; Panax notoginseng, sweet, slightly bitter, and warm, disperses blood stasis, relieves pain, and stops bleeding without leaving blood stasis; Ligusticum chuanxiong, pungent and warm, regulates qi, relieves depression, invigorates blood circulation, and relieves pain; Mutton, pungent and warm, warms the kidneys, assists yang, strengthens the heart, and unblocks the meridians; Ophiopogon japonicus, sweet, slightly bitter, and cold, nourishes yin, generates fluids, clears the heart, and eliminates irritability; Pueraria lobata, sweet, pungent, and cool, raises yang, relieves muscle tension, unblocks the meridians, and stops dizziness. 3. This traditional Chinese medicine formula covers the three core pathogenesis of coronary heart disease: blood stasis, phlegm turbidity, and deficiency of both qi and yin; sea buckthorn and white crane ganoderma lucidum replenish qi and blood, dilate coronary arteries and lower lipids; salvia miltiorrhiza, notoginseng, chuanxiong, and bitter gourd fruit enhance blood circulation, remove blood stasis, and have anticoagulant and thrombolytic effects; yam, ophiopogon japonicus, epimedium, and mutton nourish yin and moisten the pulse, warm yang and strengthen the heart; kudzu root, motherwort, and heart-returning herb guide the medicine to the heart and promote diuresis and unblock the meridians. 4. This traditional Chinese medicine formula conforms to the principles of monarch, minister, assistant, and guide in the combination of herbs. Blood-activating herbs are combined with yin-nourishing herbs to prevent pungent and dry herbs from damaging yin; yang-warming herbs are combined with heat-clearing herbs to avoid the transformation of warming and tonifying herbs into fire; epimedium and mutton shavings warm the kidneys and assist yang to strengthen the heart, while kudzu root raises clear yang to improve blood supply to the brain and heart, thus regulating the heart, kidneys, and pulses; it also takes into account the complications of coronary heart disease, with kudzu root lowering blood pressure, ophiopogon japonicus lowering blood sugar, and ganoderma lucidum promoting sleep, making it suitable for people with "three highs" (hypertension, hyperlipidemia, and hyperglycemia). 5. The traditional Chinese medicine formula of this invention has been verified by a rat myocardial ischemia-reperfusion injury model experiment, and has a good effect on the prevention and treatment of coronary heart disease. Detailed Implementation

[0010] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions will be clearly and completely described below in conjunction with specific embodiments of the present invention.

[0011] Example 1 A traditional Chinese medicine formula for the prevention and treatment of coronary heart disease is prepared according to the following method, including the following steps. S1. Weigh out the following Chinese medicinal materials according to the following ratio: 100g of sea buckthorn, 100g of white crane lingzhi grass, 100g of yellow yam, 100g of bitter gourd, 100g of salvia miltiorrhiza, 100g of philoxeroides, 60g of notoginseng, 60g of chuanxiong, 60g of bistorta, 60g of ophiopogon japonicus, 60g of yanghong tan, 50g of motherwort, 50g of kudzu root, and 50g of epimedium. Mix them together and process them into 600-mesh ultrafine powder. S2. Take half of the total amount of the above ultrafine powder, add 1000ml of purified water and 500ml of 75-degree liquor, and mix well in a stirrer. S3. Heat to 100℃ and hold for 30 minutes, then let it cool naturally to room temperature for 1 hour; S4. Mix the remaining half of the ultrafine powder with the ultrafine powder mixture after high-temperature treatment, dry it, and then make it into pellets.

[0012] Example 2 A traditional Chinese medicine formula for the prevention and treatment of coronary heart disease is prepared according to the following method, including the following steps. S1. Weigh out the following Chinese medicinal materials according to the following ratio: 100g of sea buckthorn, 100g of white crane lingzhi grass, 100g of yellow yam, 100g of bitter gourd, 100g of salvia miltiorrhiza, 100g of purslane, 60g of notoginseng, 60g of chuanxiong, 60g of bistorta, 60g of ophiopogon japonicus, 60g of yanghong tan, 50g of motherwort, 50g of kudzu root, and 50g of epimedium. Mix them together and process them into 1000-mesh ultrafine powder. S2. Take half of the total amount of the above ultrafine powder, add 1000ml of purified water and 500ml of 75-degree liquor, and mix well in a stirrer. S3. Heat to 100℃ and hold for 30 minutes, then let it cool naturally to room temperature for 1 hour; S4. Mix the remaining half of the ultrafine powder with the ultrafine powder mixture after high-temperature treatment, dry it, and granulate it to obtain the final product.

[0013] Experiments were conducted using rats to verify the results. Thirty clean-grade Wistar inbred rats, all male, weighing 245-320g (mean 278.2±22.2g), were housed in a clean-grade environment. Rats were divided into a control group, a model group, and the experimental group of Example 1. Each experimental group received the drug via gavage at a dose of 0.20 g / kg, once daily for 21 days. The control and model groups received an equal volume of distilled water via gavage once daily for 21 consecutive days. One hour after the last gavage administration, except for the control group where the left coronary artery was not ligated, all other groups underwent myocardial ischemia-reperfusion injury. After the myocardial ischemia-reperfusion injury, blood was collected from the abdominal aorta, centrifuged, and serum was obtained. Serum LDH and CK activities were detected using a kit. After blood was collected from the abdominal aorta, the heart was removed, and non-myocardial tissues such as blood vessels and fat were removed. Surface moisture was absorbed with filter paper. Parallel atrioventricular grooves were used to cut the heart into 1.5-2.0 mm thin slices, totaling 5 slices. The slices were stained in Tris-HCl buffer containing 1% TCC pre-warmed at 37℃ for 15 min. The slices were then fixed in 4% formaldehyde solution for 1 h. Normal myocardium appeared red, while infarcted myocardium appeared grayish-white. The mass of normal and infarcted myocardium was measured separately, and the percentage of infarcted myocardium to the total mass of the myocardium (the sum of infarcted and normal myocardium) was calculated, which is the extent of myocardial infarction.

[0014] The results of serum LDH and CK activity assays in rats are as follows: Group quantity LDH activity U / L CK activity U / L control group 10 156.82±26.24** 135.78±24.68** Model group 10 435.63±55.62 213.24±32.84 Example 1 10 226.75±62.45** 112.74±22.52** Note: Compared with the model group, ***P<0.001, **P<0.01, *P<0.05 As shown in the table above, compared with the model group, the serum CK and LDH activities of rats in each experimental group of this application were reduced, indicating that the composition of this application can alleviate myocardial ischemia-reperfusion injury in rats to a certain extent and reduce the leakage of CK and LDH from myocardial cells.

[0015] The results of myocardial infarction extent in rats are shown in the table below. Group quantity Myocardial infarction range % control group 10 4.12±0.54** Model group 10 26.41±3.21 Example 1 10 12.52±1.84** Note: Compared with the model group, ***P<0.001, **P<0.01, *P<0.05 As shown in the table above, compared with the model group, the formulation of this application can reduce the myocardial infarction range caused by myocardial ischemia-reperfusion in rats.

[0016] Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of the technical features. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A traditional Chinese medicine formula for the prevention and treatment of coronary heart disease, characterized in that: The ingredients, in parts by weight, include 100 parts of sea buckthorn, 100 parts of white crane lingzhi grass, 100 parts of yellow yam, 100 parts of bitter gourd, 100 parts of salvia miltiorrhiza, 100 parts of purslane, 60 parts of notoginseng, 60 parts of chuanxiong, 60 parts of bistorta, 60 parts of ophiopogon japonicus, 60 parts of mutton, 50 parts of motherwort, 50 parts of kudzu root, and 50 parts of epimedium.

2. The method for preparing a traditional Chinese medicine formula for the prevention and treatment of coronary heart disease according to claim 1, characterized in that, Includes the following steps, S1. Weigh out the Chinese medicinal materials according to the specified proportions, mix them together, and process them into 600-1000 mesh ultrafine powder; S2. Take half of the total amount of the above ultrafine powder, add 1000ml of purified water and 500ml of 75-degree liquor, and mix well in a stirrer. S3. Heat to 100℃ and hold for 30 minutes, then let it cool naturally to room temperature for 1 hour; S4. Mix the remaining half of the ultrafine powder with the ultrafine powder mixture after high-temperature treatment, dry it, and then make it into pellets or granules.

3. The application of the traditional Chinese medicine formulation according to claim 1 or the traditional Chinese medicine preparation prepared by the preparation method according to claim 2 in the prevention and treatment of coronary heart disease.